EUVIMEDEUVIMED entdecken
EvaluationsstudieMultizentrische StudieOpen Access · CC BY 4.0

Evaluation of homologous recombination testing in ovarian carcinoma

Vera M Witjes, Joanne A de Hullu, Angela van Remortele, Lilian Vreede, Efraim H Rosenberg, Saskia A G M Cillessen, Floris H Groenendijk, Elisabeth M P Steeghs, Laura Moonen, Arjen R Mensenkamp, Arja Ter Elst, Wendy W J de Leng und 2 weitere

Virchows Archiv · 2026

DOI: 10.1007/s00428-026-04432-2 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Virchows Archiv, 2026. Verfasst von Vera M Witjes und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Homologous Recombination, Ovarian Neoplasms, Recombinational DNA Repair. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homologous recombination deficiency (HRD) testing may be used to stratify ovarian carcinoma (OC) patients for PARP inhibitor therapy. In the Netherlands, different NGS-based assays are used to assess genomic instability as a hallmark of HRD. We evaluated the uniformity of HRD testing. Firstly, interlaboratory assessments of 10 tumors were performed in 8 centers. 71 out of the 77 (92%) successful tests were concordant. Results were more consistent in OC with a pathogenic variation (PV) or promoter methylation of a homologous recombination repair (HRR) gene (97%) than in those without (87%). Secondly, concordance between BRCA1 / RAD51C promoter methylation and HRD was assessed in 244 samples without a PV in HRR genes. BRCA1 / RAD51C promoter methylation was present in 38 out of 100 (38%) samples classified as HRD, and absent in all ( n = 144) non-HRD samples ( p < 0.001). Lastly, pathology reports from 765 HRD tests were reviewed to evaluate routine diagnostics. Testing was successful in 695 (91%) cases. HRD detection rates were higher in high-grade serous OC compared to other histological subtypes (49% versus 12%, p < 0.001). The five HRD assays varied significantly in HRD detection rates in high-grade serous OC. The results support the applicability of genomic instability analyses to assess HRD, while also highlighting the need to improve harmonization across different assays when HRD is used for therapeutic decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Homologous RecombinationOvarian NeoplasmsRecombinational DNA RepairFemaleHumansMiddle AgedBRCA1 ProteinDNA MethylationDNA-Binding ProteinsGenomic InstabilityPoly(ADP-ribose) Polymerase InhibitorsPromoter Regions, Genetic

Stichwörter der Autor:innen

BRCAGenomic instabilityHomologous recombination deficiencyOvarian cancerPARP inhibitorsQuality control

Substanzen

BRCA1 ProteinBRCA1 protein, humanDNA-Binding ProteinsPoly(ADP-ribose) Polymerase InhibitorsRAD51C protein, human

Autor:innen und Institutionen

  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Pathology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Department of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Förderung

  • KWF Kankerbestrijding

Zitieren

APA

Witjes, V. M., de Hullu, J. A., van Remortele, A., Vreede, L., Rosenberg, E. H., Cillessen, S. A. G. M., Groenendijk, F. H., Steeghs, E. M. P., Moonen, L., Mensenkamp, A. R., Ter Elst, A., de Leng, W. W. J., Hoogerbrugge, N., & Ligtenberg, M. J. L. (2026). Evaluation of homologous recombination testing in ovarian carcinoma. Virchows Archiv. https://doi.org/10.1007/s00428-026-04432-2

Vancouver

Witjes VM, de Hullu JA, van Remortele A, Vreede L, Rosenberg EH, Cillessen SAGM, et al. Evaluation of homologous recombination testing in ovarian carcinoma. Virchows Archiv. 2026. doi:10.1007/s00428-026-04432-2

BibTeX
@article{Witjes2026,
  author = {Witjes, Vera M and de Hullu, Joanne A and van Remortele, Angela and Vreede, Lilian and Rosenberg, Efraim H and Cillessen, Saskia A G M and Groenendijk, Floris H and Steeghs, Elisabeth M P and Moonen, Laura and Mensenkamp, Arjen R and Ter Elst, Arja and de Leng, Wendy W J and Hoogerbrugge, Nicoline and Ligtenberg, Marjolijn J L},
  title = {Evaluation of homologous recombination testing in ovarian carcinoma},
  journal = {Virchows Archiv},
  year = {2026},
  doi = {10.1007/s00428-026-04432-2}
}
Kostenlos starten →